tbuckley/cabot-search huggingface dataset:
Mammary adipose tissue and cancer cell growth: The role of adipose tissue in the tumor microenvironment
Authors: P. A. Carroll, L. Healy, J. Lysaght, M. Griffin, B. Dunne, Mr. T. Boyle, J. V. Reynolds, M. J. Kennedy, G. Pidgeon, E. M. Connolly
Journal: Journal of Clinical Oncology (2009)

e22009 Background: Worldwide, the prevalence of obesity is rapidly increasing, correlating with a direct increase in cancer rates 1 . Adipose tissue is considered an important endocrine organ producing several important hormones and cytokines including leptin and adiponectin. Mechanisms for the role of obesity in cancer states includes the excess or unregulated secretion of adipocytokines from adipose tissue, and potentially the metabolic syndrome (a cluster of co-morbidities linked to metabolic dysregulation). Mammary adipose tissue is proposed to play a vital role in the microenvironment of normal and tumour states within the breast 2 . Breast adipose tissue is a good candidate to investigate effects of obesity and metabolic disturbances on cancer states. Methods: Peritumoural (PT) adipose tissue adjacent to the tumour and distal adipose tissue (D) within the breast was sampled in 10 patients. The tissue was processed and cultured for 72hrs in serum free minimal cytokine media. A-MB-231 and MCF-7 breast cancer cell lines were then cultured with this adipocyte conditioned media (ACM) and cell proliferation response was then measured using BrDU assays. The adipocytokine profile at the mRNA and protein level was measured in ACM and adipose tissue for comparative differences using RT-PCR, ELISA and Cytokine Profiler technology. Results: ACM from both sites promoted tumour cell survival. There was however, a differential cell proliferation response noted between the peritumoural (PT) ACM and that from the distant (D) ACM. Pro-inflammatory mediators (VEGF, TNF-α, EGF) were also demonstrated a trend to be differentially expressed between the 2 sites. Conclusions: Proliferation of breast cancer cell lines occurs in response to ACM, with differential effects seen between peritumoural ACM and distant ACM. This may be mediated through increased pro-inflammatory or pro- mitogenic adipocytokine production in adipose tissue surrounding tumour. Further analysis will determine what role obesity and the metabolic syndrome plays in the results noted. No significant financial relationships to disclose.
Docetaxel (D) and cisplatin (C) induction chemotherapy followed by concurrent thoracic radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study.
Authors: J. Casal, S. Varela, U. Anido, M. Lázaro, J. L. Fírvida, S. Vazquez-Estevez, M. Villanueva, M. Amenedo, M. Caeiro, A. Gomez
Journal: Journal of Clinical Oncology (2010)

7090 Background: Concurrent chemoradiation is recommended as the evidence-based approach for the management of patients (p) with locally advanced NSCLC and a good performance status. The aim of our study was to evaluate the feasibility of induction chemotherapy with D-C followed by concurrent TRT and biweekly D-C. Methods: 85 p with locally advanced NSCLC, stage IIIAN2/IIIB (no pleural T4), were included in a phase II study consisting with three cycles of D 75 mg/m2 on day 1 and C 40 mg/m2 days 1-2 every 3 weeks and, if no surgery, then underwent concurrent TRT (60-66Gys, 180 cGys/d) with D 30 mg/m2 and C 30 mg/m2 every 2 weeks for four courses. Median follow-up: 12.6 months. Results: The p characteristics were: mean age 61 years (44-75); male/female 77/8; ECOG PS 0/1 in 25/60 p; squamous/adeno/large cell carcinoma: 51.8%/28.2%/20%; stage IIIAN2 20 p (23.5%) and stage IIIB 49 p (76.5%). 79 p were evaluable for response and 82 p for toxicity. Induction D-C response: 2 CR, 47 PR (RR 62%; CI95%:51-73), 21 SD (26.6%) and 9 PD (11.4%). 9 p underwent surgery: 1 pCR, 5 pPR, 1 pEE and 2 p unresectable. 55 p completed concurrent TRT with 8 CR, 37 PR (RR 81.8%; CI95%:71-92), 3 SD and 7 PD. The median progression-free survival (PFS) was 9 months (CI95%:8-14) and median overall survival (OS) was 18 months (CI95%:13-23). The PFS and OS at 1/2 years were 45%/20% and 64%/42% respectively. A total of 235 cycles of D-C were given (2.8 per p); main toxicities (NCI-CTC 3.0) per p grade (g) 1-2/3-4 (%) were as follows: neutropenia 10.9/25.6; anemia 30.4/3.5; nausea/vomiting 30.4/7.3; fatigue 28/0; diarrhea 17/9.7; there were ten episodes of febrile neutropenia and there was one treatment-related death. Main toxicities per p in concurrent TRT (D-C doses: 211, 3.6 per p) were: g1-2 neutropenia/anemia 12/34.4%; g1-2/3 esophagitis in 51.7/1.7% and g1-2 pneumonitis in 24.5%; there was one treatment-related death. Conclusions: Induction chemotherapy with D-C followed of concurrent TRT and biweekly D-C is a feasible treatment option for locally advanced NSCLC, showing good clinical activity and tolerability with acceptable long-term survival. No significant financial relationships to disclose.
Role of N-acetyltransferase polymorphisms in hepatitis B-related hepatocellular carcinoma: impact on risk of smoking
Authors: M. W. Yu, C. I. Pai, S. Y. Yang, T. J. Hsiao, H. C. Chang, S. M. Lin, Y. F. Liaw, P. J. Chen, C. J. Chen
Journal: Gut (2000)
Concurrent chemoradiotherapy with weekly platinum for patients with unresectable/locally advanced SCCHN and comorbidities.
Authors: S. A. Limaye, S. N. Horowitz, A. Thomas, N. Kohn, B. Mehrotra
Journal: Journal of Clinical Oncology (2010)

e16024 Background: Concurrent chemoradiotherapy (CRT) with cisplatin 100mg/m2, given every 3 wks, is a standard treatment option for unresectable/locally advanced squamous cell carcinoma of head and neck (SCCHN). However, many pts are unable to tolerate the toxicity of standard dose Cisplatin. We are presenting the two year follow up data of our previously reported study where we evaluated the efficacy and feasibility of concurrent weekly dose platinum with RT in patients who have a poor performance status (PS) and multiple comorbidities. Methods: We retrospectively identified pts treated with weekly platinum and RT for locally advanced SCCHN. Treatment response was evaluated by clinical exam, PET and CT scans. Results: 33 pt charts were identified from 2003-2007. 28 pts had upfront CRT and 5 had CRT for recurrent disease. Carboplatin AUC 2(n=11) or cisplatin 35mg/m2 (n=20) or both used alternately (n=2) were given weekly, concurrently with RT. Median duration of therapy was 6 wks. Primary disease sites: oral cavity (n=6), oropharynx (n=20), hypopharynx (n=4), and occult primary with neck disease (n=3). Stages: III (n = 4), IVA (n = 24), and IVB (n=5). PS: KPS 60% (n=13),70% (n=10), 80%(n=5), 90%(n=5). 10 pts had significant comorbidities limiting therapy with standard dose platinum. 28 pts had CRT only and 5 had surgery followed by CRT. 23 pts (73%) had CR, 3 (9%) had PR and 6 (18%) had progressive disease at the first follow-up imaging. Med. duration of follow up: 33+ mo (range 5- 71 mo). DFS at 1 yr: 86.4% (95% CI: 63.3%-95.4%) DFS at 2 yrs: 67.9% (95% CI: 44.2%-83.2%). OS at 1 yr: 92.6% (95% CI: 73.8%-98.1%) OS at 2 yrs: 66.7% (95% CI: 45.8% - 81.0%). Conclusions: The results of the two year follow up of concurrent weekly platinum and RT for unresectable/ locally advanced SCCHN are provocative. The two year DFS and OS rates are comparable with those previously reported in good PS, study eligible pts as in RTOG 91-11, and by Adelstein et al (JCO 2003 Jan 1;21(1):92-8) and Bonner et al (NEJM 2006 Feb 9;354(6):567-78). In addition to comparable and sustained survival rates in pts with poor PS and comorbidities, it is a regimen with excellent tolerability and may be considered as a reasonable option in this group of pts. No significant financial relationships to disclose.
Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group
Authors: Eva Kimby, Björn Östenstad, Peter de Nully Brown, Harald Holte, Hans Hagberg, Martin Erlanson, Ola Linden, Marie Nordström, Christer Sundstrom
Journal: Blood (2012)
P0175 : Assessment of serum glycomics (glycocirrhotest) for risk prediction of hepatocellular carcinoma development in patients with cirrhosis
Authors: X. Verhelst, D. Vanderschaeghe, L Castera, A. Geerts, N. Goutté, C. Francoz, F. Durand, N. Callewaert, H. Van Vlierberghe
Journal: Journal of Hepatology (2015)
A Potential Molecular Approach to Ex Vivo Hematopoietic Expansion With Recombinant Epidermal Growth Factor Receptor-Expressing Adenovirus Vector
Authors: Tokiharu Takahashi, Kaoru Yamada, Tomoyuki Tanaka, Keiki Kumano, Mineo Kurokawa, Tsuyoshi Takahashi, Naoto Hirano, Hiroaki Honda, Shigeru Chiba, Kohichiro Tsuji, Yoshio Yazaki, Tatsutoshi Nakahata, Hisamaru Hirai
Journal: Blood (1998)
An inexpensive photo and video capture system for fibreoptic bronchoscope
Authors: Manoj Yadav
Journal: European Respiratory Journal (2013)

Introduction: Live display on a monitor screen and capture of bronchoscopic video images can be achieved by video-bronchoscope or by using video hardware attached to fibreoptic bronchoscope, but is expensive and uses bulky equipment.

Aim: This study was done to explore the possibility of a cost effective and portable system of digital image capture during fibreoptic bronchoscopy using easily available resources and make video and photo documentation convenient and economical without using costly, bulky equipment.

Method: A simple digital camera was attached to fibreoptic bronchoscope using an adaptor (from a light bulb holder socket). The camera was connected to laptop via USB TV tuner device. Live display of bronchoscopic images was done on laptop screen and the bronchoscopic video and photos saved on laptop computer.

Results: Assembling the commonly available resources, it was possible to capture video and photos during bronchoscopy and perform bronchoscopy while watching it on laptop screen. The cost of camera and USB TV tuner device used was less than € 120.

Conclusion: Good quality digital bronchoscopic photographs and video can be obtained using this cost effective system and its use extended to teaching, reviewing, patient education and documentation. This easy to assemble, affordable, portable image capture system can be a boon for bronchoscopists especially in developing countries where fibreoptic bronchoscope is still widely used and video-bronchoscopes are mostly limited to some tertiary level institutes and corporate hospitals.
Succinate dehydrogenase in <i>KIT/PDGFRA</i> wild-type gastrointestinal stromal tumors.
Authors: K. A. Janeway, S. Kim, M. Lodish, V. Nose, P. Dahia, P. Rustin, G. D. Demetri, J. A. Fletcher, L. J. Helman, C. A. Stratakis
Journal: Journal of Clinical Oncology (2010)

10008 Background: 85% of GISTs in children are wildtype, lacking activating mutations in KIT or PDGFRA. The Carney-Stratakis Syndrome is an inherited predisposition to GIST and paraganglioma, caused by germline mutations in succinate dehydrogenase (SDH) subunits B, C or D and resulting in dysfunction of complex II of the electron transport chain. We evaluated the role of defective cellular respiration in sporadic wildtype GIST. Methods: 38 patients with KIT- / PDGFRA- wildtype GIST without a family history of paraganglioma had testing for germline mutations in SDH. Thirteen pediatric KIT- / PDGFRA- wildtype GISTs lacking somatic mutations or deletions in SDH were evaluated for SDHB expression by immunohistochemistry (IHC), and western blotting. For comparison, SDHB expression was similarly evaluated in KIT-mutant GISTs and NF-1 associated GISTs. In addition, complex II activity was measured in a subset of the pediatric KIT- / PDGFRA-wildtype GISTs and in KIT-mutant GISTs. Results: 6 of 38 patients (16%) with KIT- / PDGFRA- wildtype GIST without a family history of paraganglioma had germline mutations in SDHB (n=3), C (n=1), or D (n=2). All pediatric KIT- / PDGFRA-wildtype GISTs lacking somatic mutations or deletions in SDH had complete loss of SDHB protein expression demonstrated by both IHC and western blotting while 75% of the KIT-mutant and 100% of the NF-1 associated GISTs had strong SDHB expression and none of these tumors demonstrated complete loss of SDHB expression. Complex II activity was absent (comparable to levels seen in SDH mutant paragangliomas) in pediatric KIT- / PDGFRA- wildtype GISTs lacking somatic SDH mutations or deletions. Conclusions: A germline mutation in SDHB, C or D can cause KIT- / PDGFRA- wildtype GIST without an associated family history of paraganglioma. In the absence of SDH mutations or deletions, pediatric KIT- / PDGFRA-wildtype GISTs have complete loss of SDHB protein expression and loss of complex II activity. These findings indicate that SDHB loss and defective cellular respiration may be central mediators of oncogenesis in GISTs lacking receptor tyrosine kinase mutations. No significant financial relationships to disclose.
Abstract 15314: Mechanisms of p22phox C242T Polymorphism in Reduced TNF Alpha-Induced Nox2 Activation in Endothelial Cells
Authors: Daniel N Meijles, Jian-Mei Li
Journal: Circulation (2012)

The NADPH oxidase (Nox) by generating reactive oxygen species (ROS) is involved in the pathogenesis of many cardiovascular diseases. Several clinical studies report a single nucleotide polymorphism...
Impact of androgen deprivation therapy (ADT) on bone, cardiovascular, and endocrine outcomes: A propensity-matched analysis of 20,000 patients
Authors: S. M. Alibhai, M. Duong-Hua, R. Sutradar, N. E. Fleshner, P. Warde, A. M. Cheung, L. Paszat
Journal: Journal of Clinical Oncology (2008)

5012 Background: Several studies have suggested an increased risk of fragility fractures, acute myocardial infarction (AMI), and diabetes mellitus with continuous use of ADT in men with prostate cancer (PC). Published studies have generally been small and have been unable to adjust for other comorbidities, medications, and indications for ADT. Methods: Using linked administrative databases, we performed an observational study of men age 66 or older with PC in Ontario, Canada. The treated group (n=19,709) consisted of men who started continuous ADT for at least 6 months or underwent bilateral orchiectomy. The non-treated group also had PC, but had not received ADT. Treated and untreated groups were hard-matched on age, prior PC treatment, and year of diagnosis, and propensity-matched on comorbidities, medications, cardiovascular risk factors, prior fractures, and socioeconomic variables. Primary outcomes were development of a fragility fracture, AMI, diabetes, and hypercholesterolemia. Cox proportional hazards models were used with a frailty term to accommodate the matched design. Analyses were also done using a logistic regression model with generalized estimating equation (GEE) methods for a matched design. Results: The cohort was followed for a mean of 6.47 y. In time-to-event analyses, ADT use was associated with an increased risk of fragility fracture (hazard ratio (HR) 1.65, 95% confidence interval (CI) 1.53, 1.77) and diabetes (HR 1.16, 95% CI 1.11, 1.21) but a decreased risk of AMI (HR 0.91, 95% CI 0.84, 1.00) and hypercholesterolemia (HR 0.91, 95% CI 0.89, 0.94). Similar results were found using the logistic GEE approach. The absolute excess risk of fracture and diabetes was 3.11% (8.88% vs. 5.77%) and 2.65% (22.30% vs. 19.65%), respectively. Conclusions: Continuous ADT use for at least 6 months in men age 66 or older with PC is associated with an increased risk of fragility fracture and diabetes but not AMI or hypercholesterolemia. No significant financial relationships to disclose.
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy (CT) in early breast cancer (BC) patients
Authors: L. Del Mastro, P. Bruzzi, M. Venturini, G. Cavazzini, A. Contu, L. Gallo, F. Testore, B. Castagneto, A. Lavarello, R. Rosso
Journal: Journal of Clinical Oncology (2004)

571 Background. The prognostic and predictive role of HER2 overexpression in BC is still controversial. We retrospectively evaluated such a role in patients (pts) enrolled in a phase III trial comparing adjuvant CT with standard FEC21 (Cyclophosphamide 600, epidoxorubicin 60, 5Fluorouracil 600 mg/m2 q21 days) versus accelerated FEC14 (same drug doses but administered every 14 days with G-CSF support). Methods. Central evaluation of HER2 was performed by IHC (CB-11 MoAb) in 731 cases (60% of the trial population). HER2 was considered positive (overexpressed) in presence of a 3+ score. The prognostic role of HER2 status was assessed by fitting a proportional hazard model to the data. An interaction term representing the modification of the effect of dose-dense therapy in HER2+ pts was included in the final models. Overall survival (OS) and Event Free Survival (EFS) in pts assigned to FEC14 or FEC21 were compared separately within each HER2 subgroup. Results. Median follow-up was 6.7 years. No difference in main characteristics were observed between pts with and without HER2 assessment. Overexpression of HER2 was observed in 103 pts (14.1%) and it was a factor associate with a poor EFS (HR=1.55; 95%CI 1.05–2.28; p=0.027) and overall survival OS (HR=2.00; 95% CI 1.22–3.26, p=0.006). The potential benefit of dose-dense epirubicin-containing CT seems restricted to HER2+ patients (Table). The interaction analysis suggested that that the use of dose-dense adjuvant CT completely removed the negative prognostic effect of HER2 overexpression on EFS and partially contrasted that on OS. Conclusions. Our data indicate that HER2 overexpression is a poor prognostic factor in early BC pts and that it may be a strong predictor of the benefit of dose-dense epirubicin-containing adjuvant CT. No significant financial relationships to disclose.
Sorafenib (S) with preoperative chemoradiotherapy for extremity soft tissue sarcomas (STS) and evaluation by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
Authors: K. S. Perlewitz, W. Huang, J. B. Hayden, Z. B. Adler, A. Hung, A. Mansoor, M. L. Holtorf, S. L. Hemmingson, W. J. Woodward, C. W. Ryan
Journal: Journal of Clinical Oncology (2010)

TPS335 Background: We previously reported on the treatment of AJCC stage III extremity STS with 3 cycles of preoperative epirubicin/ifosfamide (E/I) and hypofractionated radiation (RT) followed by 3 cycles of E/I after resection (Ryan et al., Cancer 2008). Phase II studies have shown single-agent activity of S in advanced sarcoma. We hypothesize that the addition of S to our chemoradiotherapy regimen is safe and will improve outcomes by potentiating the effects on the local tumor and enhancing the effects on micrometastatic disease. DCE-MRI is a functional imaging modality that can detect changes in blood flow and/or vessel wall permeability within a tumor. The “Shutter-Speed” Model (SSM) (Li et al., Magn Reson Med 2005) is a unique method of quantitative DCE-MRI data analysis that is more accurate in estimating pharmacokinetic parameters such as Ktrans and ve compared to the conventional Tofts' model (Tofts et al., J Magn Reson Imaging 1999). These biomarkers may be useful in early assessment of activity during preoperative treatment of STS. Methods: Subjects with >5 cm, intermediate- or high- grade extremity or body wall STS with planned resection of primary tumor are eligible for this phase I trial. Subjects are treated with increasing doses of S (200, 400, 800 mg using a traditional 3+3 design) initiated 14 days prior to chemotherapy with E 30 mg/m2/day days 1-3 and I 2.5 g/m2/day days 1-3 every 21 days for 3 preoperative and 3 postoperative cycles. 28 Gy of RT is administered over 8 fractions during cycle 2 of preoperative therapy with E omitted. S is held for 1 week prior and 1 week after surgery. Our primary objective is to determine the safety and maximum tolerated dose of S in combination with E/I and RT. A correlative pilot study of 10 subjects involves DCE-MRI scanning at baseline, after 2 weeks S run-in, and after completion of preoperative therapy. We will assess the feasibility and technical considerations associated with DCE-MRI for extremity STS. Data will be analyzed using the SSM and the derived Ktrans and ve values will be used for preliminary assessment of S activity and correlation with histopathologic changes in the operative specimen. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer, Novartis, Onyx, Pfizer, Wyeth Bayer, Novartis, Onyx, Pfizer, sanofi-aventis, Wyeth Amgen, Bayer, Johnson & Johnson, Lilly, Novartis, Onyx, Pfizer, Synta, Ziopharm
Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution
Authors: C. Hosing, R. Bassett, B. Dabaja, R. Talpur, A. Alousi, S. Ciurea, U. Popat, M. Qazilbash, E.J. Shpall, Y. Oki, Y. Nieto, C. Pinnix, M. Fanale, F. Maadani, M. Donato, R. Champlin, M. Duvic
Journal: Annals of Oncology (2015)
Novel dosimetric criteria for salvage permanent brachytherapy based on 3D-cancer mapping.
Authors: Koji Okihara, Kana Kobayashi, Kazumi Kamoi, Tsuyoshi Iwata, Tsuneharu Miki
Journal: Journal of Clinical Oncology (2014)

269 Background: Salvage permanent brachytherapy (SPB) is one of treatment options in recurred men after external beam radiation therapy (EBRT). The accurate 3D correspondence between recurred cancer focus and location of seed implants using transrectal sonography (TRUS) is indispensable to design excellent dosimetry. The application of MRI-TRUS fusion targeted/systematic biopsy (Fusion-B) has enabled us to draw 3D recurred-cancer mapping. We have started SPB in men who recurred 3D-conformal EBRT using 3D-cancer mapping from Fusion-B. We introduce the novel dosimetric criteria for SPB-based on 3D cancer mapping. Methods: The patients with PSA failure (defined by Pheonix criteria) and without lymphnode/distant metastasis were enrolled in this study. In men who had suspicious recurrent focus/foci in MRI, we performed Fuision-B (ultrasound equipment: Image fusion: Koelis in France, and Biopsy: Medison in South Korea). We classified the three dosimetric patterns as follows: (1) Focal pattern: one core positive from target biopsy alone within hemilobe and GS less than 8. (2) Hemi-lobe pattern: positive cores within hemi-lobe from target/ systematic biopsies and GS less than 8. (3) Whole / focused gland pattern c/w hormonal therapy: Positive core(s) with GS greater than seven was identified regardless of positive biopsies location, or positive cores with GS less than eight from bilateral lobes. Prescribed dose to the target lesion, rV100 and uD90 were planned greater than 160Gy, 0% and less than 165Gy respectively. Results: Since August 2012, SPB has underwent in nine cases (PSA range prior to SPB: 2.22- 4.97ng/ml, age 61 to 77). In those cases, prescription dose at the 3D-conformal EBRT was 72 Gy and the duration between the 3D-conformal EBRT and SPB ranged from 41 to 107 months. The biopsy GS (-7/8-) obtained from Fuison-B distributed in 6/3 cases. Biopsy revealed single focus obtained from target biopsy in two cases. Focal and hemi-lobe pattern were chosen in two and one case, respectively. For the present, there is no re-PSA failure and G3-4 GI and GU comorbidities. Conclusions: To reduce the incidence of co-morbidity and maintain reasonable oncological outcome, it is informative to apply the 3D Cancer mapping for the SPB candidates. It is necessary to assess this criteria with the further follow-up.